PMID- 34590391
OWN - NLM
STAT- MEDLINE
DCOM- 20220126
LR  - 20220731
IS  - 1440-1819 (Electronic)
IS  - 1323-1316 (Print)
IS  - 1323-1316 (Linking)
VI  - 76
IP  - 1
DP  - 2022 Jan
TI  - Secondary Mania induced by TNF-alpha inhibitors: A systematic review.
PG  - 15-21
LID - 10.1111/pcn.13302 [doi]
AB  - A growing number of studies support a bidirectional relationship between 
      inflammation and bipolar disorders. Tumor necrosis factor-alpha (TNF-alpha) inhibitors 
      have recently attracted interest as potential therapeutic compounds for treating 
      depressive symptoms, but the risk for triggering mood switches in patients with 
      or without bipolar disorders remains controversial. Thus, we conducted a 
      systematic review to study the anti-TNF-alpha medication-induced manic or hypomanic 
      episodes. PubMed, Scopus, Medline, and Embase databases were screened for a 
      comprehensive literature search from inception until November 2020, using The 
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 
      Out of the initial 75 references, the screening resulted in the inclusion of four 
      case reports (each describing one patient) and a cohort study (in which 40 
      patients out of 7600-0.53% - experienced elated mood episodes after infliximab 
      administration). Of these 44 patients, 97.7% experienced a manic episode and 2.3% 
      hypomania. 93.2% of patients had no history of psychiatric disorder or 
      psychotropic treatment. Only 6.8% had a history of psychiatric disorders with the 
      affective spectrum (4.6% dysthymia and 2.3% bipolar disorder). The time of onset 
      of manic or hypomanic symptoms varied across TNF-alpha inhibitors with an early onset 
      for Infliximab and a later onset for Adalimumab and Etanercept. These findings 
      suggest that medications targeting the TNF-alpha pathway may trigger a manic episode 
      in patients with or without affective disorders. However, prospective studies are 
      needed to evaluate the relative risk of such side effects and identify the 
      population susceptible to secondary mania.
CI  - (c) 2021 The Authors Psychiatry and Clinical Neurosciences published by John Wiley 
      & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.
FAU - Miola, Alessandro
AU  - Miola A
AUID- ORCID: 0000-0002-2513-2718
AD  - Department of Neuroscience, University of Padova, Padova, Italy.
AD  - Padova Neuroscience Center, University of Padova, Padova, Italy.
AD  - Casa di Cura Parco dei Tigli, Padova, Italy.
FAU - Dal Porto, Veronica
AU  - Dal Porto V
AD  - Department of Neuroscience, University of Padova, Padova, Italy.
FAU - Meda, Nicola
AU  - Meda N
AUID- ORCID: 0000-0003-1114-3632
AD  - Department of Medicine, University of Padova, Padova, Italy.
FAU - Perini, Giulia
AU  - Perini G
AD  - Department of Neuroscience, University of Padova, Padova, Italy.
AD  - Padova Neuroscience Center, University of Padova, Padova, Italy.
AD  - Casa di Cura Parco dei Tigli, Padova, Italy.
FAU - Solmi, Marco
AU  - Solmi M
AD  - Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
AD  - Department of Mental Health, The Ottawa Hospital, Ottawa, ON, Canada.
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), 
      University of Ottawa, Ottawa, ON, Canada.
FAU - Sambataro, Fabio
AU  - Sambataro F
AUID- ORCID: 0000-0002-7423-0090
AD  - Department of Neuroscience, University of Padova, Padova, Italy.
AD  - Padova Neuroscience Center, University of Padova, Padova, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20211102
PL  - Australia
TA  - Psychiatry Clin Neurosci
JT  - Psychiatry and clinical neurosciences
JID - 9513551
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Cohort Studies
MH  - Humans
MH  - Infliximab/adverse effects
MH  - Mania/*chemically induced
MH  - Tumor Necrosis Factor Inhibitors/*adverse effects
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
PMC - PMC9298409
OTO - NOTNLM
OT  - TNF inhibitors
OT  - bipolar disorders
OT  - disease-modifying antirheumatic drugs
OT  - immune system
OT  - manic switch
EDAT- 2021/10/01 06:00
MHDA- 2022/01/27 06:00
PMCR- 2022/07/20
CRDT- 2021/09/30 07:36
PHST- 2021/08/09 00:00 [revised]
PHST- 2021/06/01 00:00 [received]
PHST- 2021/09/13 00:00 [accepted]
PHST- 2021/10/01 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/09/30 07:36 [entrez]
PHST- 2022/07/20 00:00 [pmc-release]
AID - PCN13302 [pii]
AID - 10.1111/pcn.13302 [doi]
PST - ppublish
SO  - Psychiatry Clin Neurosci. 2022 Jan;76(1):15-21. doi: 10.1111/pcn.13302. Epub 2021 
      Nov 2.